Prime Medicine, Inc.

NasdaqGM:PRME Stock Report

Market Cap: US$513.0m

Prime Medicine Future Growth

Future criteria checks 2/6

Prime Medicine's earnings are forecast to decline at 1.5% per annum while its annual revenue is expected to grow at 21% per year. EPS is expected to grow by 12.7% per annum. Return on equity is forecast to be -165.9% in 3 years.

Key information

-1.5%

Earnings growth rate

12.7%

EPS growth rate

Biotechs earnings growth27.1%
Revenue growth rate21.0%
Future return on equity-165.9%
Analyst coverage

Good

Last updated25 Oct 2024

Recent future growth updates

Recent updates

Prime Medicine's Promising Pipeline: PM359 And Cash Burn Concerns

Sep 04

Here's Why We're A Bit Worried About Prime Medicine's (NASDAQ:PRME) Cash Burn Situation

Sep 04
Here's Why We're A Bit Worried About Prime Medicine's (NASDAQ:PRME) Cash Burn Situation

Prime Medicine Stock: Only For The Most Patient Of Investors

Jun 20

Is Prime Medicine (NASDAQ:PRME) In A Good Position To Invest In Growth?

May 14
Is Prime Medicine (NASDAQ:PRME) In A Good Position To Invest In Growth?

Prime Medicine's Investment Potential: A Deep Dive Into Innovation And Gene Editing

Jan 28

Is Prime Medicine (NASDAQ:PRME) In A Good Position To Deliver On Growth Plans?

Aug 25
Is Prime Medicine (NASDAQ:PRME) In A Good Position To Deliver On Growth Plans?

We're Not Very Worried About Prime Medicine's (NASDAQ:PRME) Cash Burn Rate

May 12
We're Not Very Worried About Prime Medicine's (NASDAQ:PRME) Cash Burn Rate

Will Prime Medicine (NASDAQ:PRME) Spend Its Cash Wisely?

Jan 24
Will Prime Medicine (NASDAQ:PRME) Spend Its Cash Wisely?

Earnings and Revenue Growth Forecasts

NasdaqGM:PRME - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202621-193-233-22810
12/31/20256-199-204-20011
12/31/202412-195-206-19013
6/30/20241-217-205-196N/A
3/31/20241-204-201-192N/A
12/31/2023N/A-198-174-165N/A
9/30/2023N/A-173-164-152N/A
6/30/2023N/A-158-157-143N/A
3/31/2023N/A-151-139-123N/A
12/31/2022N/A-142-148-132N/A
9/30/2022N/A-171-126-114N/A
6/30/2022N/A-158-103-94N/A
3/31/2022N/A-126-85-80N/A
12/31/2021N/A-184-38-34N/A
9/30/2021N/A-118-27-23N/A
12/31/20205-5-6-6N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: PRME is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: PRME is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: PRME is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: PRME's revenue (21% per year) is forecast to grow faster than the US market (8.9% per year).

High Growth Revenue: PRME's revenue (21% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: PRME is forecast to be unprofitable in 3 years.


Discover growth companies